. ® was developed before the emergence of the Omicron variant and Evusheld therefore, at the time when it was being considered by the MHRA, there was limited understanding of its efficacy against Omicron, or the duration of any protection it may afford. Subsequently, the UK Health Security Agency (UKHSA) was tasked with carrying out further testing on the t...